EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
About this item
Full title
Author / Creator
Liu, Rui , Li, Zongwei , Chen, Rui , Fang, Zhihong , Liu, Zhiqiang and Liu, Huan
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Myelomatous bone disease is a complication characterized by lytic bone lesions, reduced bone formation, bone pain, and increased fracture risk. Understanding these underlying mechanisms is crucial for developing effective therapeutic approaches. Here we show the role of enhancer of zeste homolog 2 (EZH2) in bone lesions induced by myeloma cells. Ou...
Alternative Titles
Full title
EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_270cb7404535498ca54b949584e594bf
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_270cb7404535498ca54b949584e594bf
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-025-56506-5
